相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group
Olav Dahl et al.
ACTA ONCOLOGICA (2009)
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers
Jan P. A. Baak et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Adjuvant therapy for stage II and III colorectal cancer
Aimery de Gramont et al.
SEMINARS IN ONCOLOGY (2007)
EZH2 promotes proliferation and invasiveness of prostate cancer cells
R. J. Bryant et al.
PROSTATE (2007)
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer
K Collett et al.
CLINICAL CANCER RESEARCH (2006)
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
IM Bachmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer
Eeva Salminen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Activated p53 suppresses the histone methyltransferase EZH2 gene
XH Tang et al.
ONCOGENE (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
AP Bracken et al.
EMBO JOURNAL (2003)
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer:: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study
CJ Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
